옵션 체인은 다양한 행사가격과 만기일에 대한 Veren의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Veren에 대한 시장 심리를 평가합니다..

Veren (NYSE:VRN) 주식, 옵션 체인

Veren

Veren Inc is an oil producer company. It is engaged in acquiring, developing, and holding interests in petroleum assets operations across western Canada.

D-Wave Quantum Inc.

Equities

Mid Cap

News

Movers

Trading Ideas

HSAI

IONQ

ORLA

PTGX

QBTS

RGTI

SMTC

이 중형주들은 지난주에 가장 좋은 성과를 냈습니다. 당신의 포트폴리오에 있나요? 1. D-웨이브 퀀텀(NYSE:QBTS)의 주식은 회사가 4분기 수주가 1억 8,300만 달러로 전년 대비 502% 증가했다고 보고한 후 95.95% 상승했다.

D-웨이브 퀀텀과 아이온큐 등 지난주 급등한 중형주 8종목 (3월 10일-3월 14일)

Veren Inc

Verona Pharma plc - American Depositary Shares

Verona Pharma PLC

VERANO HLDGS CORP by Verano Holdings Corp.

Verano Holdings Corp

Varonis Systems Inc

Verint Systems Inc

Equity Lifestyle Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>) reported quarterly earnings of $0.83 per share which met the analyst consensus estimate. This is a 6.41 percent increase over earnings of $0.78 per share from the same period last year. The company reported quarterly sales of $387.33 million which missed the analyst consensus estimate of $398.72 million by 2.85 percent. This is a 0.20 percent increase over sales of $386.57 million the same period last year.

Earnings

Earnings Misses

Equity Lifestyle Props Q1 FFO $0.83, Inline, Sales $387.33M Miss $398.72M Estimate

WIIM

CALX

Calix shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 guidance above estimates. Additionally, the company announced an authorized increase to its stock repurchase program.

Calix shares are trading higher following strong Q1 earnings and upbeat Q2 guidance.

Flexsteel Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXS#NASDAQ">FLXS</a>) reported quarterly earnings of $1.13 per share which beat the analyst consensus estimate of $0.88 by 28.41 percent. This is a 68.66 percent increase over earnings of $0.67 per share from the same period last year. The company reported quarterly sales of $113.97 million which beat the analyst consensus estimate of $111.94 million by 100.00 percent. This is a 100.00 percent decrease over sales of $107.22 million the same period last year.

Earnings Beats

FLXS

Flexsteel Industries Q3 2025 Adj EPS $1.13 Beats $0.88 Estimate, Sales $113.97M Beats $111.94M Estimate

Shenzhen, China, April 21, 2025 (GLOBE NEWSWIRE) -- Meiwu Technology Company Limited ("WNW" or the "Company"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) announced today that it received a formal notification from the Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company's ordinary shares, no par value each (the "Ordinary Shares") to maintain a minimum bid price of $1.00 per share.
The Nasdaq staff made this determination of compliance after the closing bid price of the Company's Ordinary Shares has been at $1.00 per share or greater for the last 10 consecutive business days from April 1, 2025, to April 14, 2025. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and this bid price deficiency matter is now closed.

Meiwu Technology Company Regains Compliance With Nasdaq

Guidance

Calix Sees Q2 Adj. EPS $0.18-$0.24 vs $0.15 Est., Revenue $221M-$227M vs $210.527M Est.

Clearwater Will Deliver Industry's First Unified, Cloud-Native Front-to-Back Platform for Institutional Investors
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclearwateranalytics.com%2F%3Futm_medium%3Dthird-party%26utm_source%3Dpress-release%26utm_campaign%3Dbw-enfusionclose&amp;esheet=54241058&amp;newsitemid=20250421999466&amp;lan=en-US&amp;anchor=Clearwater+Analytics&amp;index=1&amp;md5=da67dbce39b66fd5c79f99f56ecc261e">Clearwater Analytics</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>), the most comprehensive technology platform for investment management, today announced the successful completion of its acquisition of Enfusion, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFN#NYSE">ENFN</a>), a leader in software-as-a-service (SaaS) solutions for the investment management and hedge fund sectors, in a deal valued at approximately $1.5 billion.
This strategic combination positions Clearwater as the industry's first single-instance, multi-tenant, cloud-native platform to unify front, middle, and back-office investment operations. By integrating portfolio and order management, IBOR, risk, accounting, and client reporting into one seamless solution, Clearwater is replacing the fragmented legacy model with a modern platform that empowers faster decision-making and operational clarity across asset classes and geographies.
"The close of the Enfusion acquisition marks a major milestone—not just for Clearwater, but for the entire investment management industry," said Sandeep Sahai, Chief Executive Officer of Clearwater Analytics. "By combining Enfusion's strong front-office capabilities with our established middle and back-office solutions, we are accelerating our journey towards a fully integrated, cloud-native front-to-back investment management platform. This combination will eliminate costly data handoffs and inefficiencies stemming from fragmented workflows, empowering our clients to make faster, data-driven decisions with complete confidence in their data."
"I'm immensely proud of what the Enfusion team has achieved and the shareholder value we delivered. Enfusion's focus on innovation and client requirements created a world-class disruptive technology platform, fundamentally changing how our clients execute their operational workflows, implement investment strategies, manage portfolios, and optimize data insights," said Oleg Movchan, former CEO of Enfusion. "By joining forces with Clearwater, we're opening up amazing possibilities for the next wave of innovation in investment technology. I couldn't be more optimistic about how this combination will benefit our clients and transform the industry."
Today's institutional investors—asset managers, insurers, pensions, endowments, and sovereign funds—face increasing complexity across portfolios, geographies, and asset classes. Many still rely on outdated systems that silo data and delay insight. The expanded Clearwater platform will address these challenges by offering:
<ul>
<li>Seamless integration across front, middle, and back-office workflows</li>
<li>A single security master and data model for consistent, real-time views of positions, performance, and risk</li>
<li>An open architecture that connects to a growing ecosystem of partners and capabilities</li>
</ul>
"Enfusion adds proven front-office depth to the Clearwater platform, giving our clients real-time access to portfolio and order management, IBOR, risk, and reporting—all in one system," said Neal Pawar, President, Head of Asset Management at Clearwater Analytics and former Chief Operating Officer at Enfusion. "The operational benefits are immediate: no batch processing, no manual reconciliation, and no duplication of data. Clients now have a shared, live view of their portfolios and operations—enabling faster execution, stronger risk oversight, and a platform that evolves with them. This is the new foundation for institutional investment technology and operations."
Clearwater's growth in asset management—its largest market segment—is expected to accelerate, with Enfusion's strength in the hedge fund space and the ability to integrate Enfusion's front office capabilities with Clearwater's middle and back office. This will result in a meaningful expansion of Clearwater's Total Addressable Market.
The acquisition also significantly expands Clearwater's international presence. Enfusion generates 38% of its revenue from Europe and Asia, supported by strong teams in London, Mumbai, Bangalore, Singapore, and Hong Kong. Clearwater will now serve clients from key global hubs including Boise, New York, Edinburgh, and New Delhi, providing localized support and delivery at scale.

CWAN

ENFN

Clearwater Analytics Successfully Completes Its Acquisition Of Enfusion In Deal Valued At ~$1.5B

2025 Financial Guidance
The Company forecasts 2025 revenue in the range of $2.140 billion to $2.240 billion, representing growth of 1.5% to 6.2% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $378.0 million to $402.0 million. Additionally, full year 2025 EBITDA is expected in the range of $462.0 million to $492.0 million. Based on forecasted 2025 revenue of $2.140 billion to $2.240 billion and GAAP net income of $378.0 million to $402.0 million, diluted earnings per share (GAAP) is forecasted in the range of $12.26 to $13.04. This guidance assumes a full year 2025 tax rate of 15.5% to 16.5%, interest income of $15.8 million, and 30.8 million diluted shares outstanding. This guidance does not include the potential impact of any share repurchases the Company may make pursuant to the share repurchase program after March 31, 2025.

MEDP

Medpace Sees FY25 EPS $12.26-$13.04 Vs $12.27 Est.; Revenue $2.14B-$2.24B Vs $2.149B Est.

Two prominent Fed voiced issued strong public defenses of the central bank&#8217;s independence on Monday, calling out President Donald Trump&#8216;s attacks on Chair Jerome Powell as politically <a href="https://www.benzinga.com/topic/jerome-powell">dangerous and economically destabilizing.</a>
Speaking Monday on CNBC, Richard Fisher, former president of the Dallas Fed, warned that Trump's repeated attacks on Powell could inflict serious long-term damage on the credibility of the Federal Reserve and the broader U.S. economy.
"The one thing you don't want to have happen is for the Fed to become politicized," Fisher said.
Fisher added that even if Trump could fire Powell, which remains legally uncertain, it would be a self-defeating move.
"I don't think it's in the president's interest to sack him. The markets would react extremely negatively," he said.
Fisher also highlighted that current uncertainty has already paralyzed corporate decision-making, referencing companies like United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>), which recently offered dual earnings forecasts due to macroeconomic unpredictability.
"I think the president, frankly, is undermining his own case." "No business can make a decision here," Fisher said. "That uncertainty has been generated by the executive branch."
When asked whether Trump could legally demote or remove Powell, Fisher pointed to historical precedent—most notably in 1979, when President Jimmy Carter reassigned then-Fed Chair G. William Miller to Treasury Secretary after a period of poor economic performance and appointed Paul Volcker in his place. 
"I hope it doesn't come to push and shove," he said. "If it does, we're going to see further spread widening, higher interest rates and pressure that damages long-term confidence in the economy."
Fisher also pushed back on the assumption that Fed rate cuts would lower market interest rates, pointing out that recent episodes of easing were followed by yield spikes in longer-term bonds.
"After they cut 50 basis points and then did three more cuts, yields went up—not down. The 10-year rose by 100 basis points," Fisher said. "So even if you force cuts, the market may not respond how you think."
Ultimately, Fisher painted a picture of a market hamstrung by political volatility and a Fed cornered by noise from the White House.
&#8220;Forget about the stock market, the FED will always act if the credit markets become dysfunctional.&#8221;
<h3 class="wp-block-heading">Goolsbee: Interference Means &#8216;Higher Inflation, Worse Growth&#8217;</h3>
Echoing Fisher's concerns, Austan Goolsbee, President of the Federal Reserve Bank of Chicago, said earlier on <a href="https://www.cnbc.com/2025/04/21/chicago-feds-goolsbee-says-fed-independence-is-critically-important-for-its-inflation-fight.html">CNBC's Squawk Box</a> that interfering with the Fed's independence would erode the institution's credibility and lead to long-term economic pain.
"Fed independence is critically important," Goolsbee said. "When there is interference over the long run, it's going to mean higher inflation, worse growth and higher unemployment."
Although Goolsbee declined to comment directly on Trump's statements, his message was clear: monetary credibility depends on political neutrality, especially when inflation-fighting resolve is needed.
"Just look at the countries where they don't have Fed independence. Inflation is higher, unemployment is higher, growth is worse," he added.
U.S. financial markets came under heavy pressure Monday, with stocks, bonds and the dollar falling in unison, a rare and unsettling signal of deepening investor distrust.
The U.S. Dollar Index (DXY), tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), slid to its lowest level since April 2022.
The S&amp;P 500, mirrored by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), sank 3.3% in one of its steepest single-day drops of the year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44903750/gold-price-soars-to-record-highs-eyes-best-2-month-rally-since-2011-on-blockbuster-etf-buying">Gold Price Soars To Record Highs, Eyes Best 2-Month Rally Since 2011 On Blockbuster ETF Buying</a></li>
</ul>
Photo: RozenskiP / Shutterstock.com

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

ETFs

PowerShares DB US Dollar Index Bullish Fund

Top Fed Voices Defend Powell, Slam Trump's Attack On Central Bank Independence

Calix Q1 2025 Adj. EPS $0.19 Beats $0.13 Estimate, Sales $220.242M Beat $206.976M Estimate

Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) reported quarterly earnings of $3.67 per share which beat the analyst consensus estimate of $3.06 by 19.93 percent. This is a 14.69 percent increase over earnings of $3.20 per share from the same period last year. The company reported quarterly sales of $558.57 million which beat the analyst consensus estimate of $527.15 million by 5.96 percent. This is a 9.30 percent increase over sales of $511.04 million the same period last year.

Medpace Hldgs Q1 EPS $3.67 Beats $3.06 Estimate, Sales $558.57M Beat $527.15M Estimate

AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) reported quarterly earnings of $0.67 per share which missed the analyst consensus estimate of $0.81 by 17.28 percent.

AZZ Q4 2025 GAAP EPS $0.67 Misses $0.81 Estimate

Broadcom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) stock traded lower on Monday after Huawei announced it was preparing a new artificial intelligence (AI) chip as an alternative <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44906106/whats-going-on-with-nvidia-stock-monday-2">to Nvidia&#8217;s H20 line.</a>
The Details: Broadcom, along with the broader semiconductor industry, is moved lower Monday following Huawei&#8217;s announcement. Huawei&nbsp;intends to start delivering its advanced 910C AI chip to customers in China as early as next month, according to Reuters.
The chip matches the performance of Nvidia's H100 by combining two 910B processors into a single unit using advanced integration techniques. President Donald Trump's administration <a href="https://www.benzinga.com/news/global/25/04/44828742/nvidia-stock-is-tumbling-after-hours-heres-why">recently implemented licensing</a> requirements for selling Nvidia's H20 and <a href="https://www.benzinga.com/news/25/04/44900227/amd-stock-drops-amid-ai-chip-export-ban-whats-going-on">select AMD chips</a> to China.
Broadcom shares may be trading lower as investors evaluate the competitive risk from Huawei and its potential impact on Broadcom's presence in the Chinese market. Ongoing concerns about tariffs and trade restrictions may also be weighing on sentiment across the chip sector.
AVGO Price Action: Broadcom shares closed 2.80% lower at $166.21 on Monday, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Related Link: • <a href="https://www.benzinga.com/25/04/44908743/mp-materials-stock-is-tumbling-monday-heres-why-investors-are-dumping-shares">MP Materials Stock Is Tumbling Monday: Here&#8217;s Why Investors Are Dumping Shares</a>
Photo: Shutterstock

Tech

AVGO

What's Going On With Broadcom Shares Monday?

Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) reported quarterly earnings of $1.13 per share which missed the analyst consensus estimate of $1.17 by 3.42 percent. The company reported quarterly sales of $795.000 million which missed the analyst consensus estimate of $797.069 million by 0.26 percent. This is a 7.14 percent increase over sales of $742.000 million the same period last year.

ZION

Zions Bancorp Q1 2025 GAAP EPS $1.13 Misses $1.17 Estimate, Sales $795.000M Miss $797.069M Estimate

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 15 years by 4.46% on an annualized basis producing an average annual return of 14.73%. Currently, Thermo Fisher Scientific has a market capitalization of $159.15 billion. 
Buying $1000 In TMO: If an investor had bought $1000 of TMO stock 15 years ago, it would be worth $7,810.59 today based on a price of $421.85 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745266511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth This Much Today

Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares are trading lower Monday after Benchmark lowered its price target on the stock <a href="https://www.benzinga.com/tech/25/04/44896693/boeing-secures-new-stocks-of-crucial-nuts-and-bolts-used-in-737-max-production-amid-chinas-import-ban-report">from $250 to $215.</a>
What To Know: The firm still maintains a Buy rating, but the reduction reflects growing concern over Boeing's ongoing production issues and a challenging operating environment.
According to Benchmark's first-quarter 2025 preview, Boeing is facing multiple short-term disruptions, including persistent supply chain problems, regulatory uncertainties and tariff-related complexity. A fire at a major fastener supplier and issues with GE engines have only worsened delays, making it difficult for the company to meet delivery expectations.
The report emphasizes that Boeing is still producing below long-term demand levels, suggesting the real issue isn't demand but rather the company's inability to ramp up supply. Analysts highlighted that while the long-term fundamentals remain intact — especially the duopoly with Airbus — the path to recovery is taking longer than previously expected. Ongoing complications, such as FAA hurdles and internal production setbacks, continue to weigh on investor sentiment.
Despite the challenges, Benchmark remains positive on Boeing&#8217;s long-term free cash flow trajectory, though it now sees slower momentum in the near term. The firm lowered its price target accordingly to reflect the new timeline for improvement, cutting it by $35. 
BA Price Action: Boeing shares were down 1.58% at $159.34 at the time of publication Monday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="535" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21154030/Screenshot-2025-04-21-at-15.40.05-1024x535.png" alt="" class="wp-image-880617" style="width:388px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21154030/Screenshot-2025-04-21-at-15.40.05-1024x535.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21154030/Screenshot-2025-04-21-at-15.40.05-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21154030/Screenshot-2025-04-21-at-15.40.05-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21154030/Screenshot-2025-04-21-at-15.40.05.png 1490w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44904179/wall-street-sinks-dollar-slides-as-trump-ramps-up-fed-attacks-whats-driving-markets-monday">Wall Street Sinks, Dollar Slides As Trump Ramps Up Fed Attacks: What&#8217;s Driving Markets Monday?</a></li>
</ul>
Photo: Shutterstock.

Travel

What's Going On With Boeing Shares Today?

FFNW

First Financial Northwest Board Declares Initial Liquidating Distribution Of $22/Share Or $203M, Representing ~95% Of Anticipated Proceeds To Ultimately Be Distributed

Ryan Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAN#NYSE">RYAN</a>) ("Ryan Specialty"), a leading international specialty insurance firm, is pleased to announce that it has signed a definitive agreement to acquire certain assets of USQRisk Holdings, LLC ("USQ"). USQ will become a part of the alternative risk business within Ryan Specialty.
Terms of the transaction were not disclosed. The acquisition is expected to close during the second quarter of 2025.
The acquisition brings approximately $11 million of incremental operating revenue to Ryan Specialty, based on the 12 months ended December 31, 2024. This figure has not been audited. &nbsp;

RYAN

Ryan Specialty Signs Definitive Agreement To Acquire Certain Assets Of USQRisk Holdings; Terms Not Disclosed; Deal Expected To Close In Q2, 2025

Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) today announced that its board of directors increased the authorization to repurchase the Company's common stock by an additional $100 million under the existing stock repurchase program.
Under the repurchase program, repurchases can be made from time to time using a variety of methods, which may include open market purchases, privately negotiated transactions or otherwise, all in accordance with the rules of the Securities and Exchange Commission and other applicable legal requirements. The specific timing, price and size of the purchases will depend on prevailing stock prices, general economic and market conditions, and other considerations consistent with the Company's capital allocation strategy. The stock repurchase program does not obligate Calix to purchase any dollar amount or number of shares of common stock and the program may be suspended or discontinued at any time.

Buybacks

Calix Increases Stock Repurchase Authorization By Additional $100M Under Existing Stock Repurchase Program

WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) reported quarterly earnings of $1.01 per share which beat the analyst consensus estimate of $0.98 by 3.06 percent. This is a 2.88 percent decrease over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $3.55 billion which beat the analyst consensus estimate of $3.53 billion by 0.47 percent. This is a 8.92 percent increase over sales of $3.26 billion the same period last year.

Comments

Veren

Veren (VRN) 옵션

Veren (NYSE:VRN) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌